0 Views
0 Likes
0 Shares
0 Comments
Read article ↗

Paula Escobar

View profile →

Article

Real-World Outcomes with the KEYNOTE-522 Regimen in Early-Stage Triple-Negative Breast Cancer

Published: Reading: 1 min

Topic overview

This real-world study evaluates outcomes of the KEYNOTE-522 neoadjuvant immunotherapy regimen (pembrolizumab plus chemotherapy) in early-stage triple-negative breast cancer patients. The research examines whether pathologic complete response rates observed in clinical trials translate to routine clinical practice settings.

Keywords

Triple-negative Breast Cancer Neoadjuvant Immunotherapy Pembrolizumab Pathologic Complete Response Keynote-522 Breast Oncology Surgical Outcomes

Hashtags

#TripleNegativeBreastCancer #Immunotherapy #BreastOncology #NeoadjuvantTherapy

Full article text

Full article text not available for this entry
How to cite: Paula Escobar. Real-World Outcomes with the KEYNOTE-522 Regimen in Early-Stage Triple-Negative Breast Cancer. GlobalCastMD Medical Library. 2025-02-01. https://library.globalcastmd.com/article/13680?via_playbook=200&via_space=paula-escobar

Comments

Loading comments...